Patients of type two diabetes got some relief yesterday after a new oral drug to manage the disease was launched.
The drug, called Trajenta, improves glycemic control, diet and exercise in adults.
Its introduction was announced during a scientific conference in Nairobi by Boehringer Ingelheim, one of the world’s leading pharmaceutical companies.
Ayman Eissa, head of Boehringer Ingelheim, said lack of awareness and an increasing prevalence of the disease had become obstacles to reducing the rise of diabetes.
The drug is available only as prescription medicine upon recommendation by a doctor. It is simple. effective and safe, the experts said.
Ayman
said, “Lack of awareness and an increasing prevalence of type 2 diabetes are critical obstacles to overcoming the rise of diabetes in Kenya. At Boehringer, we believe that Kenya and the wider
African continent has an opportunity to reduce the burden of the disease by working towardsdeveloping comprehensive protocols towards managing type 2 diabetes. That is why our work in Kenya and across
Africa
focuses on facilitating quality care while also adding more value to overall health systems.”
